肥胖的奥米克革命:从分子特征到临床解决方案
Mohammad Mustafa1, Amr A Arafat1,2, Waleed Alhazzani1,3
1Health Research Center, Ministry of Defense Health Services, Riyadh, Kingdom of Saudi Arabia.
Molecular omics
|October 24, 2025
概括
奥米克技术揭示了肥胖的分子亚型,为个性化风险预测和治疗策略提供了新的生物标志物,超出了BMI等传统指标. 这种精确的方法旨在改善患者分层和治疗向,以改善肥胖护理.
科学领域:
- 生物医学科学 生物医学科学
- 遗传学 是一个遗传学.
- 代谢学 代谢学 代谢学
背景情况:
- 肥胖是一种复杂的多因素状况,具有重大的全球健康和经济影响.
- 由于肥胖的异质性,目前的身体质量指数 (BMI) 等指标在预测个体风险和治疗反应方面存在局限性.
- 欧米茄技术的进步提供了对肥胖的潜在分子机制的更深入的了解.
研究的目的:
- 审查肥胖研究中单项和多项研究的现有证据.
- 突出与肥胖相关的新兴生物标志物和分子亚型.
- 讨论精确肥胖护理的OMIC指导框架的潜力.
主要方法:
- 基因组研究确定与肥胖相关的位置和多基因风险得分.
- 表观遗传学分析,包括DNA甲基化特征 (例如CPT1A,HIF3A).
- 代谢和蛋白质组分析以确定特定亚型的标记物 (例如,胺,BCAA,PCSK9,RBP4).
- 整合多组学数据与人工智能驱动的模型,用于患者分层.
主要成果:
- 奥米克技术已经确定了肥胖的分子亚型和候选生物标志物.
- 基因组学,表观基因组学,代谢组学和蛋白质组学为病理生理学和潜在的治疗点提供了洞察力.
- 综合型多态学和人工智能模型在将分子数据与临床表型相结合的风险建模方面表现有前途.
结论:
- Omics数据对于理解肥胖异质性和开发个性化治疗至关重要.
- 新兴的生物标志物和分子亚型可以改善患者分层,并指导治疗选择.
- 对omics发现的临床翻译需要解决队列多样性,数据协调和验证方面的挑战.
相关概念视频
01:24Obesity
1.1K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
02:02Genomics
39.6K
Genomics is the science of genomes: it is the study of all the genetic material of an organism. In humans, the genome consists of information carried in 23 pairs of chromosomes in the nucleus, as well as mitochondrial DNA. In genomics, both coding and non-coding DNA is sequenced and analyzed. Genomics allows a better understanding of all living things, their evolution, and their diversity. It has a myriad of uses: for example, to build phylogenetic trees, to improve productivity and...
39.6K
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
165
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
165
01:22PI3K/mTOR/AKT Signaling Pathway
5.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.3K
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
245
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
245
01:28Insulin: The Receptor and Signaling Pathways
2.7K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
2.7K